Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap831.57M
Enterprise Value692.04M
Trailing P/E28.02
TBPH
(NASDAQ)Theravance Biopharma, Inc.
$16.02-- (--)
Loading... - Market loading
Theravance Biopharma (TBPH) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)10.24
Forward Price/Sales8.05
Price/Book (mrq)3.53
Price/Tangible Book (mrq)3.53
Price/FCF (ttm)3.38
Price/OCF (ttm)3.37
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue8.62
EV/Earnings23.58
EV/EBITDA13.04
EV/EBIT13.91
EV/FCF2.84
Stock Price
Current price, 52-week range, and moving averages
Current Price$16.02
1-Day Change-2.40%
52-Week High$21.03
52-Week Low$7.90
52-Week Change75.61%
YTD Change-12.73%
1-Year Change75.80%
50-Day MA$17.24
200-Day MA$15.36
Avg Volume (30 day)506.79K
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding51.91M
Book Value per Share$4.48
Net Cash per Share$3.16
FCF per Share$4.69
Analyst Price Targets & Consensus
Wall Street analyst ratings and 12-month price targets (90 days)
Price Target$16.25
Target Upside/Downside1.44%
Analyst ConsensusHold
Analyst Count5
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin62.59%
EBITDA Margin (ttm)66.07%
EBIT Margin (ttm)61.95%
Operating Margin (ttm)-40.85%
Pretax Margin (ttm)58.81%
Profit Margin (ttm)36.53%
FCF Margin (ttm)303.11%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Equity (ttm)12.61%
Return on Assets (ttm)7.06%
Return on Invested Capital (ttm)30.16%
Return on Capital Employed (ttm)13.16%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue80.33M
Gross Profit50.27M
Operating Income-32.81M
Pretax Income47.24M
Net Income29.34M
EBITDA53.07M
EBIT49.76M
Diluted EPS$0.57
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow243.70M
Capital Expenditures224.00K
Free Cash Flow243.48M
Growth Rates (YoY)
Year-over-year growth metrics
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)415.46M
Cash & Securities (mrq)174.77M
Net Cash (mrq)163.86M
Net Cash per Share$3.16
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)44.59M
Working Capital (mrq)317.29M
Total Equity (mrq)232.68M
Book Value per Share$4.48
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)9.48
Quick Ratio (mrq)9.48
Debt/Equity (mrq)0.19
Debt/EBITDA (ttm)0.84
Debt/FCF (ttm)0.18
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Payout Ratio (Earnings)0.00%
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield3.57%
FCF Yield29.61%
Buyback Yield0.08%
Total Shareholder Yield0.08%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score1.10
Piotroski F-Score4/9
Fair Value & Intrinsic Value
Lynch fair value, Graham number, and valuation models
Graham Number$7.55
Graham Upside/Downside-52.33%
Frequently Asked Questions About Theravance Biopharma Statistics
What are the key financial metrics for TBPH?
Theravance Biopharma, Inc. (TBPH) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is TBPH's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Theravance Biopharma is overvalued or undervalued.
How do I read TBPH's profitability ratios?
Theravance Biopharma's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do TBPH's debt ratios indicate?
The financial health section shows Theravance Biopharma's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is TBPH's dividend analysis?
The dividend section covers Theravance Biopharma's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.